Phase 3 trial shows subcutaneous TEPEZZA matches IV efficacy for Thyroid Eye Disease with 77% proptosis response.

Amgen announced positive Phase 3 trial results for TEPEZZA administered via subcutaneous injection using an on-body injector, showing a 77% proptosis response rate in moderate-to-severe active Thyroid Eye Disease (TED) patients, comparable to intravenous TEPEZZA. The trial demonstrated a clinically meaningful average proptosis reduction of 3.17 mm at 24 weeks and improvements in other symptoms like double vision and quality of life. Safety was consistent with known profiles, with mild injection site reactions noted. These results could expand treatment options by offering a more convenient administration method while maintaining efficacy. Full results will be presented at a medical congress.